Stay updated on RO6958688 in CEA+ Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the RO6958688 in CEA+ Solid Tumors Clinical Trial page.

Latest updates to the RO6958688 in CEA+ Solid Tumors Clinical Trial page
- Check3 days agoChange DetectedA 2024 *Nature Communications* article reporting results from two Phase 1 trials of the CEA-CD3 bispecific antibody cibisatamab, with or without atezolizumab, was added to the study’s publication list.SummaryDifference0.1%

- Check10 days agoChange DetectedThe record now presents details for the completed Phase 1 RO6958688 study, including its design, eligibility criteria, study locations, interventions, and outcome measures. Study registration dates and related publications are also displayed.SummaryDifference61%

- Check17 days agoChange DetectedThe footer now displays site revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check31 days agoChange DetectedA general NIH announcement about terminology changes appears above the 403 error message. The site revision label also changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check45 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1 while the page continues to display a 403 error.SummaryDifference0.2%

- Check59 days agoChange DetectedThe study page is now a 403 Forbidden error page, replacing the usual study details with a simple error view. This indicates restricted access to the study information and navigation options on the page.SummaryDifference19%

Stay in the know with updates to RO6958688 in CEA+ Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the RO6958688 in CEA+ Solid Tumors Clinical Trial page.